A Randomized Open-Label Study to Investigate the Impact of Bone Marker Feedback at 3 Months on Adherence to Monthly Oral Bonviva in Women With Post-Menopausal Osteoporosis Supported by a Patient Relationship Program
Phase of Trial: Phase IV
Latest Information Update: 26 Feb 2017
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Roche
- 10 Jun 2017 Biomarkers information updated
- 02 Dec 2008 Status changed from active, no longer recruiting to completed, based on information from ClinicalTrials.gov.
- 19 Jun 2006 New trial record.